Tejnaksh Healthcare has released its FY26 annual report showing a dip in both standalone and consolidated revenue and profit compared to FY25. The company will hold its 19th AGM on September 29, 2026, where shareholders will vote on key director re-appointments and related party transactions. No dividend has been recommended for the fiscal year.
Tejnaksh Healthcare FY26 Financials: Revenue Down to 1,078 Lakhs
Standalone PAT declined to 137.98 Lakhs; Consolidated PAT dropped to 118.11 Lakhs.
Reader Takeaway: Operating revenue declined year-on-year across segments; no dividend declared for shareholders in FY 2025-26.
What just happened
Tejnaksh Healthcare Ltd has published its Annual Report for the fiscal year ended March 31, 2026. The company reported a significant contraction in financial performance, with consolidated revenue from operations falling to 1,078.69 Lakhs from 1,289.71 Lakhs in the previous year. Net profit (PAT) on a consolidated basis also slipped to 118.11 Lakhs, down from 223.05 Lakhs in FY 2024-25.
Why this matters
The financial results highlight a challenging fiscal period for the healthcare entity, marked by lower topline and bottom-line growth. The upcoming 19th Annual General Meeting (AGM), scheduled for September 29, 2026, will be the primary forum for shareholders to address these results and vote on corporate governance matters, including the re-appointment of Independent Director Mr. Suhas Vasantrao Thorat for a second five-year term.
Related Party Transactions
The company is seeking shareholder approval for material related-party transactions with Tej Vedaant Healthcare Private Limited, Promoter Dr. Ashish Rawandale, and Tejnaksh Healthcare Foundation. These transactions are capped at 100 Lakhs per transaction type per year and the company maintains that all dealings are on an arm’s length basis.
Governance and Audit
The Statutory Auditor, M/s. Maheshwari & Co., issued a clean report with no qualifications, reservations, or adverse remarks. Similarly, the secretarial audit conducted by N S Dave & Associates reported no issues requiring board explanation.
What to track next
Investors should monitor the AGM proceedings on September 29, 2026, particularly the voting outcome on related-party transactions and the general outlook provided by the management regarding the recovery of revenue growth in the current fiscal year.